ATXS

Astria Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website astriatx.com
Employees(FY) 45
ISIN US04635X1028

Performance

-2.55%

-1.95%

-22.59%

+6.34%

+24.48%

YTD

+58.02%

Profile

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

Advanced Technical Analysis

Technical Analysis of ATXS 2024-12-20

The stock's Moving Average Score of 10 indicates a strong bearish sentiment, while the Oscillators Score of 50 reflects a neutral stance. Overall, the combined Technical Score of 30 reinforces a bearish outlook, suggesting caution for potential investors.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ATXS

Stock Rank

Recent News & Updates

2024-12-11 08:00
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE(Business Wire)
2024-12-10 19:00
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE(Businesswire)
2024-12-09 19:00
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis(Yahoo Finance)
2024-12-03 16:10
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Business Wire)
2024-12-03 03:10
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Businesswire)
2024-11-13 16:10
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update(Business Wire)
2024-11-13 08:00
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference(Business Wire)
2024-11-13 03:10
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update(Businesswire)
2024-11-12 19:00
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference(Businesswire)
2024-11-04 16:10
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Business Wire)
2024-11-04 03:10
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Businesswire)
2024-10-30 08:00
Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting(Business Wire)
2024-10-29 20:00
Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting(Businesswire)
2024-10-21 08:00
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting(Business Wire)
2024-10-20 20:00
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting(Businesswire)
2024-10-18 08:50
Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth(Simply Wall St.)
2024-10-16 20:16
Astria Therapeutics' navenibart gains orphan medicinal status from EC(Pharmaceutical-business-review)
2024-10-16 08:00
European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema(Business Wire)
2024-10-02 16:10
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Business Wire)
2024-10-02 04:10
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Businesswire)
2024-09-30 08:00
Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema(Business Wire)
2024-09-29 20:00
Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema(Businesswire)
2024-09-27 08:00
Astria Therapeutics to Present at Upcoming Global Angioedema Forum(Business Wire)
2024-09-26 20:00
Astria Therapeutics to Present at Upcoming Global Angioedema Forum(Businesswire)
2024-09-19 08:00
Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress(Business Wire)
2024-09-18 20:00
Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress(Businesswire)
2024-09-04 16:10
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Business Wire)
2024-09-04 04:10
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Businesswire)
2024-08-30 08:00
Astria Therapeutics to Present at Upcoming Bradykinin Symposium(Business Wire)
2024-08-29 20:00
Astria Therapeutics to Present at Upcoming Bradykinin Symposium(Businesswire)

Page 1 of 6

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.